Haas R J, Belohradsky B, Dickerhoff R, Eichinger K, Eife R, Holtmann H, Goetz O, Graubner U, Peller P
Klin Padiatr. 1985 Nov-Dec;197(6):477-80. doi: 10.1055/s-2008-1034025.
26 patients with acute leukemia and other malignancies susceptible to varicella were vaccinated during maintenance chemotherapy. Vaccination was done with OKA strain of live attenuated varicella vaccine developed by Takahashi 1974. All recipients showed no adverse clinical reactions. There was no spread of vaccine virus to others. Seroconversion was 94% in seronegative patients. In those having low antibody titers before vaccination in 56% booster effect was demonstrable. None of the seroconverted recipients contracted varicella in spite of documented contact exposure. Vaccine zoster was not observed. The results suggest that in immunocompromised children live varicella vaccination has a protective effect against varicella infection which has a described mortality rate up 7% in this patients.
26例患有急性白血病及其他易患水痘的恶性肿瘤患者在维持化疗期间接种了疫苗。使用的是高桥1974年研制的OKA株减毒活水痘疫苗。所有接种者均未出现不良临床反应。疫苗病毒未传播给他人。血清阴性患者的血清转化率为94%。在接种前抗体滴度较低的患者中，56%表现出增强效应。尽管有明确的接触暴露，但所有血清转化的接种者均未感染水痘。未观察到疫苗性带状疱疹。结果表明，对于免疫功能低下的儿童，接种活水痘疫苗对水痘感染具有保护作用，在这类患者中水痘感染的死亡率高达7%。
